Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011

      -- Company reports increased revenue from grain and oilseed processing enzymes; enters strategic partnership to progress animal health & nutrition pipeline products --


      News provided by

      Verenium Corporation

      Aug 09, 2011, 04:05 ET

      Share this article

      Share this article


      SAN DIEGO, Aug. 9, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported a summary of recent Company highlights and financial results for the second quarter and six months ended June 30, 2011.

      "I am very pleased with the progress we've made in terms of product revenues and partnership negotiations in the first half of the year," said James E. Levine, President and Chief Executive Officer at Verenium. "In the second quarter we saw significant growth and diversification of product revenues through our Grain and Oilseed Processing products.  In addition, we entered into an important collaboration with Novus International Inc. to develop multiple products for the animal health and nutrition market, demonstrating the value of Verenium's product development capabilities in the large and growing global industrial enzymes market."

      Company Highlights

      Since the beginning of 2011, Verenium has made significant progress on both operational and financial fronts.  Recent accomplishments include:

      Operational/Industry Performance:

      Animal Health and Nutrition

      • Announced a strategic collaboration with Novus International Inc. to jointly develop and commercialize a suite of new animal health and nutrition enzyme products from Verenium's late-stage product pipeline.

      Grain Processing

      • Grew 2011 year-to-date revenues from the Company's grain processing enzymes, including Fuelzyme® alpha-amylase, Deltazym® GA L-E5 glucoamylase, Veretase® alpha-amylase and Xylathin™ xylanase, by 35% over the same period in 2010; and
      • Grain processing has grown to represent 31% of 2011 year-to-date product revenues from 25% during the same period in 2010.

      Oilseed Processing

      • Achieved a 100% increase in 2011 year-to-date revenue from Purifine® PLC over the same period in 2010 due to higher utilization at higher prices to our existing customers.

      Corporate/Financial:

      • Increased total product revenue by 11% to $27.5 million for the first half of 2011, compared to $24.9 million for the same period in 2010;
      • Increased 2011 year-to-date product revenue from Grain and Oilseed Processing product lines as a percentage of product revenue to approximately 40% from approximately 30% in the same period in 2010 through increasing sales of Company's newer enzymes including Fuelzyme® alpha-amylase, Xylathin™ xylanase, Veretase® alpha-amylase, Deltazym® GA L-E5 glucoamylase and Purifine® PLC;
      • Signed a lease agreement for new office and laboratory space in the Torrey Pines area of San Diego, which is targeted to commence in 2012 following the completion of construction and tenant improvements;
      • Ended the quarter with unrestricted cash and cash equivalents totaling $44.6 million and convertible notes outstanding of $44.2 million; and
      • Subsequent to the end of the second quarter, repurchased $8.2 million in principal amount of outstanding convertible notes.

      Financial Results

      In the commentary below, the historical results of the Company's ligno-cellulosic biofuels business for current and prior periods have been reclassified into discontinued operations as a result of the sale of the ligno-cellulosic biofuels business on September 2, 2010 to BP Biofuels North America LLC.

      Revenues

      Revenues for the periods ended June 30, 2011 and 2010 were as follows (in thousands):






      Three Months Ended 

      June 30,





      Six Months Ended 

      June 30,


      2011


      2010


      2011


      2010

      Revenues:








            Animal Health and Nutrition

      $          8,035


      $         8,887


      $        16,110


      $        16,841

            Grain Processing

      4,535


      3,152


      8,429


      6,239

            All other products

      1,908


      1,251


      2,971


      1,772

                 Total product

      14,478


      13,290


      27,510


      24,852

      Collaborative

      656


      390


      1,020


      1,052

      Total revenues

      $         15,134


      $       13,680


      $        28,530


      $        25,904




      Total revenues for the six months ended June 30, 2011 increased 10% to $28.5 million from $25.9 million for the same period in the prior year, with product revenues representing approximately 96% of total revenues in both periods. Product revenues for the six months ended June 30, 2011 increased 11% to $27.5 million from $24.9 million for the same period in the prior year, primarily due to an increase in revenues from grain processing enzymes, including Fuelzyme® alpha-amylase, Veretase® alpha-amylase, Deltazym® GA L-E5 glucoamylase and Xylathin™ xylanase. These products continued to gain traction in the grain ethanol markets and together with Purifine® PLC for soybean oil processing, achieved significant revenue growth over 2010.

      Product Gross Profit and Gross Margin

      Product gross profit for the six months ended June 30, 2011 increased 6% to $10.0 million from $9.5 million for the same period in prior year. Gross margin decreased to 36% of product revenue for the six months ended June 30, 2011, compared to 38% for the six months ended June 30, 2010.  Gross margin decreased primarily due to a decrease in the royalty paid as profit share from sales of Phyzyme phytase by our partner Danisco Animal Nutrition.

      Operating Expenses (excluding cost of product revenue and restructuring expense)

      Excluding cost of product revenues and restructuring, total operating expenses related to continuing operations for the six months ended June 30, 2011 decreased to $14.1 million (including share-based compensation of $0.3 million) from $16.3 million (including share-based compensation of $0.6 million) for the same period in the prior year; this is  primarily due to reimbursement of legal fees of $1.1 million for expenses incurred during 2010 for defense of the Company's noteholder lawsuit which was settled on March 23, 2011, and to initiatives to decrease general and administrative expenses. As a partial offset, research and development costs for continued investment in pipeline products showed an increase.

      Restructuring Expense

      On March 31, 2011 the Company closed its office in Cambridge, Massachusetts, resulting in a charge of $2.9 million, consisting of employee termination costs, facilities closure costs, and employee relocation costs for several employees who were relocated to San Diego.

      Operating Loss from Continuing Operations

      Operating loss from continuing operations for the six months ended June 30, 2011 was $6.0 million compared to $5.7 million for the same period in 2010. This increase is primarily reflective of restructuring expenses of $2.9 million. Excluding the impact of restructuring, operating loss from continuing operations decreased $2.7 million, primarily due to the reimbursement of legal fees and further reductions in general and administrative expenses.

      Net Income (loss) from Continuing Operations

      Net income from continuing operations for the six months ended June 30, 2011 was $2.3 million compared to a net loss of $9.9 million for the same period in 2010, on a GAAP accounting basis. Adjusted for the impact of non-cash items related to the Company's convertible debt, the Company's non-GAAP pro-forma net loss from continuing operations for the six months ended June 30, 2011 was $7.7 million compared to $9.8 million for the same period in the prior year. The Company believes that excluding the impact of these items provides a more consistent measure of operating results.  

      Balance Sheet

      The Company ended the second quarter of 2011 with $44.6 million in cash and cash equivalents, $5.0 million in restricted cash, and $44.2 million in debt at face value. Subsequent to the end of the second quarter, on July 27, 2011, the Company repurchased $8.2 million in principal amount of its outstanding convertible notes in a privately negotiated transaction. To effect this repurchase, the Company paid a total of $7.7 million in cash to a noteholder to retire principal, plus $0.2 million of accrued interest as of the closing date, leaving the Company with approximately $36 million in face value of debt at that date.

      "We are encouraged by the strong operational and financial performance achieved in the first half of the year," said Jeffrey Black, Senior Vice President and Chief Financial Officer.  "Our ability to increase product revenues and product gross profit, while at the same time lowering operating expenses and conserving cash, signifies that we are executing on our strategy to strengthen our balance sheet and position the Company for future growth."

      About Verenium

      Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

      Forward-Looking Statements

      Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2010 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

      Contacts:

      Kelly Lindenboom

      Vice President, Corporate Communications

      858-431-8580

      [email protected]

      Sarah Carmody

      Manager, Corporate Communications

      858-431-8581

      [email protected]




      Verenium Corporation

      Consolidated Statements of Operations

      (unaudited, in thousands, except per share amounts)



      Three Months Ended

      June 30,


      Six Months Ended

      June 30,



      2011


      2010



      2011



      2010

      Revenues:








      Product

      $     14,478


      $    13,290


      $    27,510


      $  24,852

      Collaborative

      656


      390


      1,020


      1,052

      Total revenue

      15,134


      13,680


      28,530


      25,904









      Operating expenses:








      Cost of product revenue

      9,392


      8,830


      17,476


      15,346

      Product gross profit

      5,086


      4,460


      10,034


      9,506

      Product gross margin

      35%


      34%


      36%


      38%

      Research and development

      2,288


      1,249


      4,920


      2,676

      Selling, general and administrative

      4,666


      6,495


      9,166


      13,582

      Restructuring charges

      82


      --


      2,920


      --









      Total operating expenses

      16,428


      16,574


      34,482


      31,604









      Operating loss from continuing operations

      (1,294)


      (2,894)


      (5,952)


      (5,700)









      Other income and expense:








      Interest and other expense, net

      (692)


      (2,127)


      (1,753)


      (4,107)

      Gain on debt extinguishment upon conversion of convertible notes

      --


      --


      --


      598

      Gain on debt extinguishment upon repurchase of convertible notes

      --


      --


      11,284


      --

      Gain (loss) on net change in fair value of derivative assets and liabilities

      518


      (786)


      (1,295)


      (718)

      Total other income (expense), net

      (174)


      (2,913)


      8,236


      (4,227)









      Income (loss) from continuing operations

      (1,468)


      (5,807)


      2,284


      (9,927)

      Discontinued operations:








      Income (loss) from discontinued operations

      --


      (6,353)


      61


      (21,729)









      Less: Loss attributed to noncontrolling interests in

      consolidated entities – discontinued operations

      --


      7,675


      --


      15,175

      Net income (loss) attributed to Verenium

      $     (1,468)


      $   (4,485)


      $      2,345


      $   (16,481)

      Basic and diluted net income (loss) per share:

      Continuing operations

      $       (0.12)


      $     (0.47)


      $        0.18


      $       (0.82)

      Discontinued operations

      $              --


      $     (0.52)


      $            --


      $       (1.79)

      Net income (loss)

      $       (0.12)


      $     (0.37)


      $        0.19


      $       (1.35)

      Shares used in computing basic and diluted net income (loss) per share

      12,606


      12,273


      12,606


      12,165






      Verenium Corporation

      Condensed Consolidated Balance Sheet Data

      (unaudited, in thousands)



      June 30,



      December 31,


      2011


      2010





      Cash and cash equivalents

      $          44,620


      $            87,929

      Restricted cash, short term

      5,000


      --

      Accounts receivable, net

      9,447


      6,708

      Inventory, net

      5,649


      5,316





      Other current assets  

      2,508


      2,694

      Restricted cash, long term

      --


      5,000

      Property and equipment, net  

      3,645


      3,134

      Other noncurrent assets  

      602


      976





      Total assets  

      $           71,471


      $         111,757









      Current liabilities, excluding deferred revenue, restructuring and liabilities of discontinued operations

      $           10,703


      $           16,849

      Deferred revenue, current  

      3,499


      894

      Accrued restructuring, current

      1,047


      --

      Convertible notes, at carrying value (face value of $44.2 million at June 30, 2011 and $74.7 million at December 31, 2010)

      48,242


      88,011

      Other long term liabilities  

      946


      1,216

      Liabilities of discontinued operations  

      683


      1,617

      Stockholders' equity  

      6,351


      3,170





      Total liabilities and

      stockholders' equity  

      $          71,471


      $         111,757








      Verenium Corporation

      Unaudited Supplemental and Non-GAAP Pro Forma Financial Information

      (in thousands, except per share amounts)


      The following unaudited supplemental and non-GAAP pro forma financial information is derived from the Company's condensed consolidated financial statements for the three and six months periods ended June 30, 2011 and 2010, as reported under GAAP. The Company believes that such supplemental and non-GAAP financial information is helpful to understand the results of operations of the business.





      Non-GAAP Pro Forma Net Loss From Continuing Operations




      Three Months Ended
      June 30,


      Six Months Ended
      June 30,


      2011


      2010


      2011


      2010

























      Income (loss) from continuing operations

      $        (1,468)


      $          (5,807)


      $         2,284


      $        (9,927)









      Adjustments:  








      Gain on debt extinguishment upon repurchase of convertible notes

      --


      --


      (11,284)


      --

      Gain on debt extinguishment upon conversion of convertible notes

      --


      --


      --


      (598)

      (Gain) loss on net change in fair value of derivative assets and liabilities

      (518)


      786


      1,295


      718

      Non-GAAP pro forma net loss from continuing operations  

      $        (1,986)


      $          (5,021)


      $        (7,705)


      $        (9,807)









      Non-GAAP pro forma net loss from continuing operations per share  

      $          (0.16)


      $            (0.41)


      $          (0.61)


      $          (0.81)












      SOURCE Verenium Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.